Replies to post #78561 on Biotech Values

[DewDiligence]

I believe Botox is already extensively off-label used in spasticity but perhaps it will be further reimbursed.

The penetration of Botox in spasticity is already respectable for an off-label indication, but spasticity is not currently a major contributor to total Botox sales in all indications. As you noted, FDA approval should greatly help with reimbursement.